Results 61 to 70 of about 412,436 (221)

Clinicopathologic Characteristics of Somatic TP53 Mutations in Philadelphia Chromosome–Negative Myeloproliferative Neoplasms: A Systematic Review

eJHaem, Volume 7, Issue 5, October 2026.
ABSTRACT Background TP53 mutations (TP53m) are uncommon in chronic‐phase Ph–negative myeloproliferative neoplasms but become enriched in myelofibrosis (MF) and accelerated/blast phase myeloproliferative (AP/BP‐MPN). Their prevalence, allelic distribution, and phase‐stratified outcomes have not been systematically synthesized.
Mahmood Aldapt, Rasha Kaddoura, Ahmed O. Saleh, Mostafa Najim, Ahmad Salem, Abdulrahman F. Al‐Mashdali, Bassam Muthanna, Ruba Adel Aweer, Marrita Rabadi, Shehab F. Mohamed   +9 more
wiley   +1 more source

Manipulating hepcidin in polycythemia vera

, 2023
In this issue of Blood, Bennett et al1 provide elegant data supporting the mounting evidence of the critical role of hepcidin, the master regulator of iron metabolism, in the pathophysiology of polycythemia vera (PV).
Girelli, Domenico, Busti, Fabiana
core   +1 more source

Next‐Generation Manufacturing: The Evolving Role of Biocatalysis in AstraZeneca

ChemBioChem, Volume 27, Issue 17, 14 September 2026.
Biocatalysis is strengthening AstraZeneca's manufacture of active pharmaceutical ingredients through faster development, robust scale‐up, and lower environmental impact. Case studies illustrate where biocatalysis delivers greatest value, while enabling platforms, teams, and partnerships shape its next phase.
Alba Diaz‐Rodriguez, Martin A. Hayes, Keith R. Mulholland, Fernando Tur, Samantha Staniland   +4 more
wiley   +1 more source

Ruxolitinib versus Standard Therapy for the Treatment of Polycythemia Vera [PDF]

, 2015
BACKGROUND Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, was shown to have a clinical benefit in patients with polycythemia vera in a phase 2 study.
Mark M. Jones, Habr, Dany, Verstovsek, Srdan, Ulrich Pirron, Griesshammer, Martin, Jean Jacques Kiladjian, Srdan Verstovsek, Kiladjian, Jean Jacques, PASSAMONTI, FRANCESCO, Pane, Fabrizio, Garrett, William, Zachee, Pierre, Pirron, Ulrich, Harrison, Claire N., Fabrizio Pane, Li, Jingjin, Claire N. Harrison, William Garrett, Shui He, Simon Durrant, Alessandro M. Vannucchi, Ruben Mesa, Jingjin Li, Dany Habr, He, Shui, Martin Griesshammer, Mesa, Ruben, Tamas Masszi, Jones, Mark M., Vannucchi, Alessandro M, Vannucchi, Alessandro M., Pierre Zachee, Masszi, Tamas, Durrant, Simon   +33 more
core   +1 more source

Myelopathy due to Spinal Extramedullary Hematopoiesis in a Patient with Polycythemia Vera

Case Reports in Orthopedics, 2017
Extramedullary hematopoiesis (EMH) occasionally occurs in patients exhibiting hematological disorders with decreased hematopoietic efficacy. EMH is rarely observed in the spinal epidural space and patients are usually asymptomatic.
Shuhei Ito, Nobuyuki Fujita, Naobumi Hosogane, Narihito Nagoshi, Mitsuru Yagi, Akio Iwanami, Kota Watanabe, Takashi Tsuji, Masaya Nakamura, Morio Matsumoto, Ken Ishii   +10 more
doaj   +1 more source

Cancer cell‐intrinsic type 1 interferon: production, signaling, and outcomes within sex‐biased, female malignancies

Molecular Oncology, Volume 20, Issue 9, Page 2135-2162, September 2026.
The cell‐autonomous roles of interferon type 1 vary based on duration and intensity. While acute, robust signaling results in cancer cell cytotoxic effects, sustained, low‐level signaling is associated with tumor‐promoting effects. This review summarizes current research of IFN‐1 in cancer and within the clinical setting, with an emphasis on female ...
Ashlyn Conant, Nora Badiner, Sharon Asariah, Kiera McGivney, Vishwa Shah, Tise Suzuki, Yevgeniya J. Ioffe, Juli J. Unternaehrer   +7 more
wiley   +1 more source

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3

Haematologica, 2011
We tested the hypothesis that levels of pentraxin high sensitivity C-reactive protein and pentraxin 3 might be correlated with cardiovascular complications in patients with essential thrombocythemia and polycythemia vera.
Tiziano Barbui, Alessandra Carobbio, Guido Finazzi, Alessandro M. Vannucchi, Giovanni Barosi, Elisabetta Antonioli, Paola Guglielmelli, Alessandro Pancrazzi, Silvia Salmoiraghi, Pio Zilio, Cosimo Ottomano, Roberto Marchioli, Ivan Cuccovillo, Barbara Bottazzi, Alberto Mantovani, Alessandro Rambaldi   +15 more
doaj   +1 more source

Clinical and Laboratory Characterization of Acquired Von Willebrand Syndrome

American Journal of Hematology, Volume 101, Issue 9, Page 2147-2156, September 2026.
ABSTRACT Acquired von Willebrand Syndrome (AVWS) is a rare bleeding disorder characterized by quantitative or qualitative defects of von Willebrand factor (VWF) in patients without a personal or family history of bleeding. It is frequently associated with systemic diseases, particularly lymphoproliferative disorders (LPDs) and myeloproliferative ...
Alessandro Ciavarella, Luciano Baronciani, Omid Seidizadeh, Paola Colpani, Elio Ingenito, Daniele Cattaneo, Maria Teresa Pagliari, Addolorata Truma, Alessandra Iurlo, Simona Maria Siboni, Flora Peyvandi   +10 more
wiley   +1 more source

Burning feet in polycythemia vera – peripheral sensorimotor axonal neuropathy with erythromelalgia

, 2015
Uwe Wollina Department of Dermatology and Allergology, Academic Teaching Hospital Dresden-Friedrichstadt, Dresden, Germany Abstract: Polycythemia vera is a rare myeloproliferative disease. Cutaneous symptoms are uncommon.
Wollina U
core  

CME: Polycythemia vera, myeloproliferative Neoplasie

, 2017
Zusammenfassung. Zusammenfassung: Myeloproliferative Neoplasien (MPN) nach den Kriterien der WHO 2016 [1] stellen eine heterogene Krankheitsgruppe dar, die durch Proliferation einer oder mehrerer hämatopoietischer Zellreihen definiert ist.
Esther Bächli, Micha Gundelfinger
core   +1 more source